In a notable move for ADMA Biologics, Inc. (NASDAQ:ADMA), Director Dr. Jerrold B. Grossman has expanded his position in the company through an open market transaction. According to regulatory filings reported on May 11, 2026, Dr. Grossman purchased 12,500 shares of common stock at a price of $8.01 per share, resulting in a total acquisition cost of $100,125. This single-transaction purchase takes place against a backdrop of recent share price volatility, as the stock currently trades at $8.41 after experiencing a 61% decline over the last twelve months.
Following this latest investment, Dr. Grossman's direct holdings in ADMA common stock total 501,384 shares. This figure is comprised of 490,694 shares of common stock and 10,690 Restricted Stock Units (RSUs). These RSUs were granted on February 9, 2026, and are scheduled to vest in full on February 9, 2027, provided that Dr. Grossman maintains his ongoing service with the company.
Beyond these direct holdings, Dr. Grossman maintains significant indirect ownership through various entities and family-related structures. These include:
- Brookwood LLC: 22,857 shares held via this entity, where Dr. Grossman serves as managing member.
- Jerrold Grossman 2019 Irrevocable Trust: 31,381 shares held through this trust, for which he acts as the investment trustee.
- Genesis Foundation Inc.: 38,294 shares held via the foundation, where Dr. Grossman serves as President.
- Spousal Ownership: 175 shares held through his wife's ownership.
The timing of this insider purchase follows a first-quarter earnings report for 2026 that fell short of market projections. ADMA Biologics reported earnings per share (EPS) of $0.19, which was lower than the anticipated $0.20. Furthermore, company revenue for the quarter reached $114.5 million, trailing the forecasted amount of $142.74 million. These results indicate that the company encountered difficulties in meeting established financial expectations during the period.
Key Market Observations
The recent activity by ADMA leadership and the company's financial performance impact several key areas:
- Insider Sentiment vs. Valuation: The decision by a director to commit over $100,000 to open market purchases can be viewed in the context of current valuation metrics. While recent earnings missed targets, analysis from InvestingPro suggests that ADMA may currently be undervalued, indicating potential upside based on Fair Value assessments.
- Financial Performance Metrics: The discrepancy between reported revenue and forecasted revenue highlights operational challenges within the biotechnology sector, specifically regarding meeting high-growth market expectations.
Risks and Uncertainties
Investors should consider several documented uncertainties:
- Earnings Volatility: The recent miss in both EPS ($0.19 vs $0.20) and revenue ($114.5 million vs $142.74 million) underscores the risk of financial performance deviating from analyst models, which can impact stock stability in the healthcare and biotech sectors.
- Price Performance Trends: The 61% decline in share price over the past year represents a significant downward trend that may influence market sentiment and investor confidence despite recent insider buying.
At present, there have been no reports of mergers or acquisitions involving ADMA Biologics, and analyst firms have not issued any new upgrades or downgrades following the most recent earnings release.